Atopic Dermatitis

>

Latest News

Lawrence Eichenfield, MD | Image credit: KOL provided
Lawrence Eichenfield, MD, reacts to accepted sNDA for roflumilast cream 0.15%

November 30th 2023

Lawrence Eichenfield, MD, reacts to the FDA's acceptance of a supplemental New Drug Application for roflumilast cream 0.15% to treat atopic dermatitis (AD) in patients aged 6 years and older.

FDA accepts sNDA for roflumilast cream 0.15% to treat atopic dermatitis | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.
FDA accepts sNDA for roflumilast cream 0.15% to treat atopic dermatitis

November 29th 2023

Worsening severity of AD in children associated with increased comorbidity onset risk | Image Credit: © Марина Терехова - © Марина Терехова - stock.adobe.com.
Worsening severity of AD in children associated with increased comorbidity onset risk

November 27th 2023

Lebrikizumab improves AD symptoms for adolescents inadequately controlled with cyclosporine | Image Credit: © arhat - © arhat - stock.adobe.com.
Lebrikizumab improves AD symptoms for adolescents inadequately controlled with cyclosporine

October 17th 2023

Tapinarof cream 1% reduces itch as early as 24 hours after application for pediatric AD | Image Credit: © Юля Шевцова - © Юля Шевцова - stock.adobe.com.
Tapinarof cream 1% reduces itch as early as 24 hours after application for pediatric AD

October 13th 2023

Video Interviews

More News

© 2023 MJH Life Sciences

All rights reserved.